Sirona Biochem Receives Positive Clinical Results of its Skin Lightening Compound TFC-1067 from China
Momentum Public Relations
Press Release: May 15, 2019
Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce results of a clinical trial performed in the Peoples Republic of China (China) using Sirona’s novel skin lightening agent TFC-1067. Sirona’s TFC-1067 once again demonstrated significant clinical lightening effect without any reported adverse effects.
A major distributor of cosmetics materials in China arranged clinical testing of TFC-1067 to be done by a select group of its key cosmetic customers. The formulation used in the studies was the same as that used in Sirona’s first clinical trial in the USA by Dr. Zoe Draelos. The clinical trial design protocols and the testing was conducted independently of Sirona by the cosmetic companies. The studies were conducted in Guangzhou, China.
A total of 60 participants were involved in the studies conducted over several sites. All participants applied the formulation with TFC-1067 twice daily to the face. Each study duration was 4 weeks. During the 4 weeks 90% of participant reported a brightening effect with TFC-1067. Sirona is informed by the distributor that a second set of trials with Sirona’s improved, next generation, formulation is underway.
Dr. Géraldine Deliencourt-Godefroy, Chief Scientific Officer of Sirona Biochem stated, “These are excellent clinical results. Based on the outcome from our first clinical trial, we are pleased to see such results for the short 4-week duration of the testing. This positive testing result on Asian skin with the observed lightening effect supports the clinical effect of TFC-1067 over different skin types. A longer trial is required to assess dyschromia which was assessed in Sirona’s US based clinical trial. Sirona will await feedback on the further testing currently ongoing in China with our new formulation.”
“No clinical safety issues were reported with TFC-1067 during the trial. TFC-1067 has shown a lightening effect over a short clinical trial on Asian skin types.” reports Dr. Howard Verrico, CEO of Sirona Biochem. “Although we prefer to conduct trials with a double blinded protocol using a comparative compound and a longer trial duration as we arranged in the USA, it was important to have these cosmetic companies perform their own clinical testing independently and be confident of the results. TFC-1067 continues to deliver excellent clinical results as anticipated by our preclinical assays. A strong commercial interest in TFC-1067 is already reported by the distributor based on current results.”
“Sirona’s team remains dedicated to work towards entering this market with a safe and effective alternative to current options. We are moving forward on building our relationship with the Chinese distributor with more positive news anticipated near term”, Dr. Verrico concluded.
The global skin lightening market is estimated to grow to US$31.2 billion by 20241. Asia makes up the largest and fastest growing segment of the market. A World Health Organization survey reported that nearly 40 per cent of women polled in China said they regularly used whitening products many of which are toxic2.
______________________________
1 https://www.factmr.com/report/309/skin-lightening-products-market
2 http://theglobalfool.com/tag/mercury/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
- Published in Business, Life Sciences, News Home, Sirona Biochem
ATW Tech Renews Contract with RAMQ
Momentum Public Relations
Press Release: May 2, 2019
ATW Tech Inc (“ATW Tech” or the “Company”) (TSX-V: ATW) announces that its division VuduMobile has renewed its contract with Régie d’assurance maladie du Québec (“RAMQ”) for an additional year without changing the amount, terms, and conditions.
RAMQ, the government health insurance board in Quebec, has integrated VuduMobile’s text messaging solution as part of its effort to better serve familial medical clinics across the province with the governmental program Rendez-Vous Santé Québec (rsvq.gouv.qc.ca).
“I am delighted that RAMQ continues to trust in VuduMobile as a strategic communication partner. Our team strives to always provide great products and exceptional service, and every retained customer is a reaffirmation that we are on the right track,” said Ghislain Dallaire, Vice President and General Manager of the VuduMobile division.
Additional information regarding ATW Tech is available on SEDAR at www.sedar.com.
The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech is a leader in financial technologies (‘fintech’), owner of several web platforms including VoxTel, VuduMobile, Option.vote and Bloomed. VoxTel offers various interactive communication, landline and mobile carrier billing phone solutions. VuduMobile is specialized in text messaging for enterprises through its unique, user-friendly and bilingual text messaging application and turnkey solutions. Option.vote offers a large scale, customizable, and secure multi-method voting system for unions, political parties, professional associations, and others looking for a way to reduce their voting costs and to improve their participation rates. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH Michel Guay Founder, president and CEO Tel.: 844.298.5932 ext. 301 mguay@atwtech.com www.atwtech.com |
Simon Bédard, CA, CPA, CFA, MBA Chief Financial Officer Tel.: 844.298.5932 ext. 304 sbedard@atwtech.com |
Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China
Momentum Public Relations
Press Release: February 26, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China’s #1 sourcing platform for the global personal care industry https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Sirona’s business development team in China, will be supported by a large Chinese cosmetic distribution company. The distribution company is working closely with Sirona through a memorandum of understanding to establish an optimal pathway to commercialize TFC-1067 into the Chinese skin lightening market. The PCHi 2019 will introduce Sirona’s technology to an estimated 75 cosmetic companies and numerous market experts. The business development team assembled has local knowledge and expertise that allows Sirona to navigate this immense opportunity.
Thanks to the efforts of PRC Partners Limited, Sirona has established a strong and experienced team with the diverse skill to navigate the optimal pathways to commercialize into this market. The global skin lightening market is estimated to grow to US$31.2 billion by 20241. Asia makes up the largest and fastest growing segment of the market.
Sirona would also like to thank the strong support for our recently announced financing which has been filed with the TSX Venture exchange. The Offering is subject to TSX Venture Exchange (“TSXV“) final acceptance of requisite regulatory filings. When approved by the TSXV, a news release will be issued by the company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Tetra Bio-Pharma unit launches Hemp Energy Drink
Momentum Public Relations
Press Release: February 19, 2019
Tetra Natural Health, a subsidiary of Tetra Bio-Pharma Inc., has made its Hemp Energy Drink available in 59 grocery stores and convenience stores in British Columbia, Alberta and Saskatchewan.
Hemp Energy Drink tasting in Kelowna on Feb. 3, 2019
In British Columbia the Hemp Energy Drink is available to consumers in Vancouver, Balfour, Burnaby, Castlegar, Clearwater, Grand Forks, Hope, Houston, Kaslo, Keremeos, Ladner, Langley, Lillooet, Nanaimo, Nelson, North Vancouver, Oliver, Osoyoos, Port Alberni, Robson, Rossland, Salt Spring Island, Simon Fraser University, Slocan Park, Squamish, Summerland, Surrey, Trail, Vernon, Victoria, West Kelowna, Whistler and White Rock.
In Alberta, the Hemp Energy Drink can be found in Athabasca, Banff, Boyle and Langdon, and in Saskatchewan in Kindersley and Tisdale.
The tastings of the Hemp Energy Drink were very popular on Feb. 2 and Feb. 3, during the Wellness Show Vancouver 2019 and at a product presentation in Kelowna. The distribution plan is expected to accelerate the penetration of HED attractive green cans in stores in the coming weeks.
“Our distribution plan is on schedule and the arrival of the Hemp Energy Drink is creating a buzz among consumers as soon as the product becomes available in store,” said Richard Giguere, chief executive officer, Tetra Natural Health. “We will accelerate the deployment of our market opening strategy in a few weeks with the arrival of 1.7 million cans of Hemp Energy Drink, of which more than 600,000 will be quickly shipped to new markets in Canada.”
Hemp Energy Drink is the first energy drink made from hemp in the country. Light, energizing, fresh, Hemp Energy Drink is licensed by Health Canada and contains fewer calories and more natural ingredients than any other energy drink. The product will soon be available in three flavours, classic, mango and raspberry, and it will be accessible in stores in a few months in all regions across Canada.
About Tetra Bio-Pharma Inc.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada-approved, and Food and Drug Administration-reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their health care providers. The company has several subsidiaries engaged in the development of an advanced and growing pipeline of biopharmaceuticals, natural health and veterinary products containing cannabis and other medicinal plant-based elements. With patients at the core of what it does, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
- Published in Business, hemp, Marijuana, Medical Marijuana, News Home, Tetra Bio Pharma
Cannara Biotech – Quebec’s largest cultivation facility
Cannara Biotech (CSE:LOVE)(FRA:8CB)
Headquartered in Montreal, Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec and one of the largest in Canada, a modern and secure 625,000-square-foot facility in Farnham, Quebec.
“Being in Quebec allows us to take advantage of the low cost of electricity and gives us a cost advantage over our competitors.” – ZOHAR KRIVOROT – CEO and Founder
Highlights
- Some 100,000 kg of cannabis production is expected per year once all 3 phases are operational. Today, phase 1 is being built with completion expected end of Q2 2019. Once completed, yield is expected at 15,000 kg.
- Cannara Biotech has raised $55M to date, has acquired 19 provisional patents for product exclusivity, and has developed 8 assorted THC/CBD infused product brands to add to their offerings.
- Low electricity cost in Quebec as well as reduced labour cost compared to the rest of Canada gives the Company a cost advantage over their competitors.
- Independent THC and CBD brands will be produced on-site accelerating speed to market.
- The Company will leverage the facility with joint-ventures to produce edibles, pet-products, cosmetics and beverages once the processing license is secured which is estimated for the end of 2019.
- The advantage of growing in an indoor facility offers lower risk of airborne infections, mold/mildew and produces a higher grade of cannabis.
- Cannara Biotech is building an online e-commerce platform (shopCbd.com) that will serve as a podium and distribution channel for US-CBD brands for the American market.
Closer look
Phase 1 will provide 130,000ft2 of growing space. Growing is expected to commence in the fall of 2019 with an estimated yield of 15,000kg.
Cannara Biotech raised $55 million from private investors during the introduction of this project and still have over $40 million in the bank with Phase 1 fully funded.
Phase 2 forecasted to be running by 2020 is 205,000ft2 and likely to yield 38,000kg per year. Phase 3 aiming to be operational in 2022 is 277,000ft2 and expected to produce 55,000kg per year. Cannara Biotech is looking to produce over 100,000kg per year once fully operational.
Currently, 300 sq. ft. space for Phase 2 is being rented by occupants that contribute to a rental revenue of $2 million per year. These earnings pay the monthly fee for the whole facility.
Cannara Biotech’s strategy is also to maximize on the low electricity rates Quebec has with its Hydro and low labour rates in Quebec.
Growing indoor cannabis often results in a higher grade of cannabis. Growing in a controlled environment, protected from many outdoor ailments and mildew creates a more consistent and desirable product for buyers and consumers.
Alongside selling cannabis to intermediaries who will transform the crop into their desired product, Cannara Biotech will have on-site independent THC and CBD brands, following the adoption of regulations on cannabis-infused edibles and beverages, that will produce and ship from the facility. Cannara Biotech’s facility will be a multi-purpose facility that will cultivate recreational cannabis and produce cannabinoid-infused products including edibles, cosmetics, pet products and beverages. These products will be shipped to stores and retail outlets in Canada and to international markets.
Cannara Biotech went public in Q1 of this year and is being traded on the CSE under the ticker “LOVE” and on the FRA under the ticker “8CB”. As of February 12th, 2019, LOVE closed at .22.
—
Isabelle Arsenault
Media Relations
MomentumPR
Crop Receives 2019 Production and Extraction Licenses for Its 2,115 Acre Nevada Hemp Operations
Momentum Public Relations
Press Release: February 14, 2019
CROP INFRASTRUCTURE CORP. (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announced today that its 49% owned subsidiary, Elite Ventures (“Elite”) reported that Hempire, the company’s Nevada tenant, has been issued with a 2019 hemp handler, hemp nursery and hemp grower licenses covering 1,350 irrigated acres on its 2,115 acres of owned or leased CBD focused lands.
A hemp handler is defined as a person who is registered by the licensing department to receive industrial hemp for processing into commodities, products or agricultural hemp seed.
The company chose to apply for its hemp grower licence, nursery and hemp handler licence in anticipation of its lab extracting and producing CBD isolate with a throughput capacity of one ton per day of raw biomass. Furthermore, the company increased the acreage size covered by its hemp licences from 240 acres of cultivation in 2018 to 1,350 acres of irrigated cultivation for 2019.
50,000 square feet of greenhouses are being erected to complement the plant starts coming out of the recently completed genetics laboratory.
CROP CEO, Michael Yorke, stated: “With the increased size and operating range of our tenant’s licenses, CROP’s Nevada CBD operations are emerging into a truly world class operation. Our land holdings, micropropagation team, strategies, drying and extraction capabilities and supply agreements will enable us to operate from seeds to isolate to sales in 2019.”
About CROP
CROP is publicly listed on the CSE and trades under the symbol “CROP”. CROP is focused on cannabis branding and real estate assets. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 1,865 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq. ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Nevada Project; the technological effects of Nevada Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
View original content:http://www.prnewswire.com/news-releases/crop-receives-2019-production-and-extraction-licenses-for-its-2-115-acre-nevada-hemp-operations-300795430.html
- Published in Business, CROP Infrastructure, hemp, Marijuana, News Home